Cormorant Asset Management’s Design Therapeutics DSGN Stock Holding History

Cormorant Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,150,000	Closed	-$32.4M	–	57
2023 Q2	$32.4M	Hold	5,150,000	–	–	1.82%	12
2023 Q1	$29.7M	Hold	5,150,000	–	–	1.96%	15
2022 Q4	$52.8M	Buy	5,150,000 +150,000	+3%	+$2.03M	3.54%	7
2022 Q3	$83.6M	Sell	5,000,000 -500,000	-9%	-$9.95M	5.84%	3
2022 Q2	$77M	Buy	5,500,000 +343,006	+7%	+$4.63M	5.82%	2
2022 Q1	$83.3M	Sell	5,156,994 -283,459	-5%	-$4.34M	6.39%	3
2021 Q4	$116M	Buy	5,440,453 +75,603	+1%	+$1.3M	6.93%	3
2021 Q3	$78.8M	Sell	5,364,850 -50,000	-0.9%	-$831K	3.2%	8
2021 Q2	$106M	Buy	5,414,850 +300,000	+6%	+$7.57M	3.6%	6
2021 Q1	$146M	Buy	+5,114,850	New	+$173M	3.26%	5

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management's DSGN Position: Q3 2023 in Review

Cormorant Asset Management sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 5,150,000 shares — an estimated $32.4M sold.

Cormorant Asset Management first reported a position in DSGN in Q1 2021 and held it in 10 quarters. The position peaked at $146M in Q1 2021. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

Cormorant Asset Management reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
Cormorant Asset Management sold 5,150,000 Design Therapeutics shares in Q3 2023, an estimated $32.4M.
Cormorant Asset Management first reported a position in Design Therapeutics in Q1 2021 and held it in 10 quarters.
Cormorant Asset Management's Design Therapeutics position peaked at $146M in Q1 2021.
87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.